🇺🇸 FDA
Patent

US 10836763

5 to 7 membered heterocyclic amides as JAK inhibitors

granted A61KA61K9/0073A61P

Quick answer

US patent 10836763 (5 to 7 membered heterocyclic amides as JAK inhibitors) held by Theravance Biopharma R&D IP, LLC expires Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Theravance Biopharma R&D IP, LLC
Grant date
Tue Nov 17 2020 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Nov 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K9/0073, A61P, A61P11/00, A61P11/06